{"paper_id":"22f1cd57-0fd9-4464-8fd0-2967e0c7ef0c","body_text":"Zusammenfassung\nGnRH-Analoga sind gegenwärtig die effektivsten Medikamente zur Regression der Endometrioseherde und zur Reduktion der endometriosebedingten Beschwerden. Kombiniert mit einer niedrig dosierten so genannten Add-back-Medikation ist die Behandlung effektiv und nebenwirkungsarm. Die verschiedenen GnRH-Analoga, die in Deutschland auf dem Markt sind, unterscheiden sich nicht hinsichtlich ihrer Wirksamkeit, jedoch haben Depotpräparationen die beste Compliance. Der gezielte Einsatz der Medikation postoperativ oder anstatt einer Operation, zur Rezidivprophylaxe oder zur Rezidivtherapie hängt von der individuellen Situation der Patientin und von Lokalisation, Aktivität, Wachstumstyp und Schweregrad der Endometriose ab.\nAbstract\nGnRH analogues are currently the most effective medications used to achieve regression of islands of endometriosis and attenuate endometriosis-related symptoms. In combination with low-dose add-back medication they are effective and their side effects are few and tolerable. The different types of GnRH analogues available in Germany do not differ in effectiveness, but patient compliance is best with depot preparations. Whether GnRH analogues are used after or instead of surgery, to prevent recurrences or to treat recurrences depends on the individual situation of the patient and on the proliferative activity, localisation, type and stage of the endometriosis.\nSimilar content being viewed by others\nLiteratur\nAbbott JA, Hawe J, Clayton RD, Garry R (2003) The effects and effectiveness of laparoscopic excision of endometriosis: a prospective study with 2–5 year follow up. Hum Reprod 18: 1222–1227\nBarhart K, Dunsmoor-Su R, Coutifaris C (2002) Effect of endometriosis on in vitro fertilisation. Fertil Steril 77: 1148–1155\nBianchi S, Busacca M, Agnoli B (1999) Effects of 3 months therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomised study. Hum Reprod 14: 1335–1337\nBusacca M, Somigliana E, Bianchi S (2001) Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III–IV: a randomised controlled trial. Hum Reprod 16: 2399–2402\nFreundl G, Gödtke K, Gnoth C (1998) Steroidal ‚add-back‘ therapy in patients treated with GnRH agonists. Gynaecol Obstet Invest 45: 22–30\nHemmings R (1998) Combined treatment of endometriosis. GnRH agonists and laparoscopic surgery. J Reprod Med 43: 316–320\nHippach M, Hinrichs I, Schweppe KW (2003) Möglichkeiten der Langzeittherapie bei rezidivierender Endometriose. Zentralbl Gynakol 125: 303\nHornstein MD, Yuzpe AA, Burry KA (1995) Prospective randomised double-blind trial of 3 versus 6 months of narfarelin therapy for endometriosis associated pelvic pain. Fertil Steril 63: 955–962\nHornstein MD, Hemmings R, Yuzpe AA (1997) Use of narfarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 68: 860–864\nHughes E, Fedorkow D, Collins J (2004) Ovulation suppression for endometriosis (Cochrane Review). The Cochrane Library, Issue 3. John Wiley & Sons Ltd, Chichester\nKampe D, Sahl AC, Schweppe K-W (2003) Prä- und postoperative Endometriosetherapie mit GnRH-Agonisten in Depotform: drei- versus sechsmonatige Behandlungsdauer. Zentralbl Gynakol 125: 304\nKennedy S, Bergqvist A, Chapron C (2005) ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 20: 2698–2704\nKiesel L, Schweppe K-W, Sillem M (1996) Should add-back therapy for endometriosis be deferred for optimal results? Br J Obstet Gynaecol 103: 15–17\nLee PA, Houk CP (2005) Outcome among adult females after treatment of central precocious puberty (CPP) with GnRH analogue (GnRH-A). 8th International Symposium on GnRH-Analogues, Geneva, Abstract 68\nLunenfeld B, Insler V (eds) (1996) GnRH-analogues: the state of the art. Parthenon, Lancaster New York\nMalinak LR (1993) Surgical treatment and adjunct therapy of endometriosis. Int J Gynaecol Obstet 40: 43–47\nMarcoux S, Maheux R, Berube S (1997) Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis. N Engl J Med 337: 217–222\nMeldrun DR, Chang RJ, Lu J (1982) Medical oophorectomy using a long-acting GnRH agonist: a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab 54: 1081–1083\nMori H, Taketani Y, Uemura T (1999) Rates of endometriosis recurrence and pregnancy 1 year after treatment with intranasal buserelin acetate (Suprecur) (a prospective study). J Obstet Gynaecol Res 25: 153–164\nMuzii L, Marana R, Caruana P (2000) Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomised trial. Am J Obstet Gynecol 183: 588–592\nParazzini F (12999) Ablation of lesions or no treatment in minimal-mild endometriosis in infertile women: a randomised trial. Gruppo Italiano per lo Studio dell‘ Endometriosi. Hum Reprod 14: 1332–1334\nPrentice A, Deary AJ, Bland E (2003) Progestagens and anti-progestagens for pain associated with endometriosis. The Cochrane Library, Issue 3. John Wiley & Sons Ltd, Chichester\nRadwanska E (1999) The effect of GnRH agonist suppression on the outcome of infertility treatment in women with endometriosis. 5th International Symposium on GnRH Analogues, Geneva, Abstract 86\nRegidor PA (2005) GnRH-agonists and endometriosis: comparison of nasal spray and depot formulations. 8th International Symposium on GnRH-Analogues, Geneva, Abstract 60\nRegidor PA, Regidor M, Ruwe B (2001) Prospective randomised study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gynecol Endocrinol 15: 202–209\nRegidor PA, Wagner I, Ruwe M (2002) Morphometric analyses of endometriotic tissues to determine their grade of activity. Gynecol Endocrinol 16: 235–243\nRickes D, Nickel I, Kropf S (2002) Increased pregnancy rates after ultra long postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertil Steril 78: 757–762\nRickes D, Weiß M, Nickel I (2003) Ovarielle Ansprechbarkeit auf rekombinante Gonadotropine nach ultralanger „Dornregulation“ mit GnRH-Analoga. Zentralbl Gynakol 125: 306\nRuwe M, Donhuijsen K, Regidor PA (1998) Endometriose: klinische, histologische und morphometrische Befunde vor und nach Gn-RH-Agonisten-Therapie. Zentralbl Gynakol 120: 391–398\nSchultze-Mosgau A, Driesinger G, Altgassen C et al. (2005) New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists. Expert Opin Investig Drugs 14: 1085–1097\nSchweppe KW (1984) Klinik und Morphologie der Endometriose. Schattauer, Stuttgart New York\nSchweppe KW (1999) Aktive – inaktive Endometriose – eine prognose- und therapierelevante Differentialdiagnose. Zentralbl Gynakol 121: 330–335\nSchweppe KW (2005) The use of GnRH analogues before and after surgery for endometriosis – clinical problems and experiences. 8th International Symposium on GnRH-Analogues, Geneva, Abstract 37\nSchweppe KW, Ring D (2002) Peritoneal defects and the development of endometriosis in relation to the timing of endoscopic surgery during the menstrual cycle. Fertil Steril 78: 763–766\nShaw RW (1992) The role of GnRH analogues in the treatment of endometriosis. Br J Obstet Gynaecol 99: 9–12\nSurrey ES, Hornstein MD (2002) Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long term follow up. Obstet Gynecol 99: 709–719\nSurrey ES, Silverberg KM, Surrey MW (2002) Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilisation – embryo transfer in patients with endometriosis. Fertil Steril 78: 699–704\nSutton CJG, Ewen SP, Whitelaw N (1994) Prospective, randomised, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild and moderate endometriosis. Fertil Steril 62: 696–700\nTempleton A, Morris JK, Parslow W (1996) Factors that affect outcome of in-vitro fertilisation treatment. Lancet 348: 1402–1406\nTinneberg HR, Manolopoulos K (2005) Reproductive medicine: comparison of depot formulations of GnRH-agonists, daily injections and nasal spray. 8th International Symposium on GnRH-Analogues, Geneva, Abstract 59\nUemura T, Shirasu K, Katagiri N (1999) Low-dose GnRH agonist therapy for the management of endometriosis. J Obstet Gynaecol Res 25: 295–301\nUemura T, Yoshikata H, Ishikawa M (1999) Effects of pre-treatment with GnRH-agonists on bone mineral density in patients with endometriosis. 5th International Symposium on GnRH-Analogues, Geneva, Abstract 45\nVercellini P, Crosignani PG, Fadini R (1999) A gonadotropin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Br J Obstet Gynaecol 6: 672–677\nWaller KG, Shaw RW (1993) Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 59: 511–515\nZupi E, Marconi D, Sbracia M (2004) Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril 82: 1303–1308\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nSchweppe, KW. GnRH-Analoga in der Endometriosetherapie. Gynäkologische Endokrinologie 4, 113–119 (2006). https://doi.org/10.1007/s10304-006-0145-x\nIssue date:\nDOI: https://doi.org/10.1007/s10304-006-0145-x","source_license":"CC0","license_restricted":false}